| Year |
Citation |
Score |
| 2019 |
Efstathiou E, Davis JW, Pisters L, Li W, Wen S, McMullin RP, Gormley M, Ricci D, Titus M, Hoang A, Zurita AJ, Tran N, Peng W, Kheoh T, Molina A, et al. Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. European Urology. PMID 31176622 DOI: 10.1016/J.Eururo.2019.05.010 |
0.605 |
|
| 2017 |
Babayan A, Alawi M, Gormley M, Müller V, Wikman H, McMullin RP, Smirnov DA, Li W, Geffken M, Pantel K, Joosse SA. Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells. Oncotarget. 8: 56066-56080. PMID 28915574 DOI: 10.18632/Oncotarget.10701 |
0.355 |
|
| 2016 |
Lam HM, McMullin R, Nguyen H, Coleman I, Gormley M, Gulati R, Brown L, Holt S, Li W, Ricci DS, Verstraeten K, Thomas S, Mostaghel EA, Nelson PS, Vessella R, et al. Characterization of an abiraterone ultraresponsive phenotype in castration-resistant prostate cancer patient-derived xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27993966 DOI: 10.1158/1078-0432.Ccr-16-2054 |
0.633 |
|
| 2016 |
McMullin R, Gupta H, Rajpurohit Y, Nguyen H, Brown L, Sondheim D, Michael G, Ricci D, Thomas S, Eva C. Abstract 3074: Addition of ARN509 and docetaxel, alone or in combination, to castration demonstrates improved efficacy and heterogeneity of molecular response in prostate cancer patient-derived xenografts Cancer Research. 76: 3074-3074. DOI: 10.1158/1538-7445.Am2016-3074 |
0.594 |
|
| 2015 |
Hubbard GK, Mutton LN, Khalili M, McMullin RP, Hicks JL, Bianchi-Frias D, Horn LA, Kulac I, Moubarek MS, Nelson PS, Yegnasubramanian S, De Marzo AM, Bieberich CJ. Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer. Cancer Research. PMID 26554830 DOI: 10.1158/0008-5472.Can-14-3280 |
0.602 |
|
| 2015 |
Efstathiou E, Li W, Gormley M, McMullin R, Ricci DS, Davis JW, Tapia EMLN, Troncoso P, Titus MA, Hoang A, Wen S, Zurita AJ, Tran N, Peng W, Kheoh T, et al. Biological heterogeneity in localized high-risk prostate cancer (LHRPC) from a study of neoadjuvant abiraterone acetate plus leuprolide acetate (LHRHa) versus LHRHa. Journal of Clinical Oncology. 33: 5005-5005. DOI: 10.1200/Jco.2015.33.15_Suppl.5005 |
0.573 |
|
| 2015 |
Lam H, McMullin R, Nguyen HM, Gormley M, Gulati R, Li W, Ricci D, Verstraeten K, Thomas S, Mostaghel EA, Nelson PS, Vessella RL, Corey E. Abstract 4313: Abiraterone acetate (AA) treatment of prostate cancer patient-derived xenografts (PDX) demonstrates heterogeneity of responses and identifies potential biomarkers of adaptive resistance Cancer Research. 75: 4313-4313. DOI: 10.1158/1538-7445.Am2015-4313 |
0.419 |
|
| 2014 |
McMullin RP, Wittner BS, Yang C, Denton-Schneider BR, Hicks D, Singavarapu R, Moulis S, Lee J, Akbari MR, Narod SA, Aldape KD, Steeg PS, Ramaswamy S, Sgroi DC. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. Breast Cancer Research : Bcr. 16: R25. PMID 24625110 DOI: 10.1186/Bcr3625 |
0.333 |
|
| 2014 |
McMullin RP, Sgroi DC. The HOXB13:IL17BR biomarker: prognostic for late recurrence and predictive for benefit from endocrine therapy Breast Cancer Management. 3: 155-163. DOI: 10.2217/Bmt.14.3 |
0.338 |
|
| 2013 |
Hubbard GK, Mutton LN, Khalili M, McMullin RP, Hicks J, Bianchi-Frias D, Nelson PS, Yegnasubramanian S, Marzo AMD, Bieberich CJ. Abstract 1086: MYC overexpression combined with Pten loss generates genomic instability and rapid metastasis in a new mouse model of lethal prostate adenocarcinoma. Cancer Research. 73: 1086-1086. DOI: 10.1158/1538-7445.Am2013-1086 |
0.596 |
|
| 2010 |
McMullin RP, Dobi A, Mutton LN, Orosz A, Maheshwari S, Shashikant CS, Bieberich CJ. A FOXA1-binding enhancer regulates Hoxb13 expression in the prostate gland. Proceedings of the National Academy of Sciences of the United States of America. 107: 98-103. PMID 20018680 DOI: 10.1073/Pnas.0902001107 |
0.796 |
|
| 2009 |
McMullin RP, Mutton LN, Bieberich CJ. Hoxb13 regulatory elements mediate transgene expression during prostate organogenesis and carcinogenesis. Developmental Dynamics : An Official Publication of the American Association of Anatomists. 238: 664-72. PMID 19191217 DOI: 10.1002/Dvdy.21870 |
0.788 |
|
| Show low-probability matches. |